Supplier Concentration Risk Disclosure: How to Present Dependency Without Alarm

The Hong Kong Stock Exchange’s (HKEX) 2024 review of listing applications revealed that supplier concentration remains one of the top three reasons for substantive comments from the Listing Division, alongside revenue recognition and related-party transactions. In its “Guidance Letter HKEX-GL86-16” (updated January 2024), the Exchange explicitly states that an issuer’s “business model must be sustainable” and that a “high degree of dependency on a single supplier or a small group of suppliers” raises questions about that sustainability. This is not merely a disclosure checkbox. The Listing Rules, specifically Main Board Rule 11.06 and GEM Rule 11.08, require a prospectus to contain “full, true and accurate” information for an investor to make an informed assessment. For a company in the IPO pipeline, a poorly framed dependency can be read as a structural fragility, triggering additional due diligence, a longer vetting process, or even a return of the application. The challenge for the CFO and their legal team is not to hide the concentration, but to present it as a managed, strategic, and defensible feature of the business model. This article outlines the specific regulatory framework, the quantitative thresholds that trigger concern, and the precise disclosure architecture required to pass HKEX scrutiny without alarming the market.

The Regulatory Framework: Defining “Material Dependency” Under HKEX Rules

The HKEX does not define “material dependency” by a single percentage. Instead, it applies a principles-based test, assessing the impact of a supplier’s loss on the issuer’s operations and financial position. The Listing Division’s practice, as codified in internal guidance and public observations, focuses on three dimensions: the revenue contribution of the supplier to the issuer’s cost of goods sold, the availability of alternative sources, and the switching costs involved.

The 30% and 50% Thresholds in Practice

While no rule states a hard number, HKEX practice, observable in published exchange correspondence and sponsor feedback, treats a single supplier accounting for over 30% of total procurement as a “notable concentration.” At 50% or above, the Exchange typically requires a dedicated risk factor section and a detailed mitigation plan. For example, in the 2023 listing of a PRC-based lithium battery materials manufacturer, the prospectus disclosed that its top two suppliers accounted for 62% and 18% of raw material purchases, respectively. The application was delayed by three months because the initial prospectus only mentioned the concentration in a general risk factor without providing the contractual protections or inventory buffers the company had in place. The final approved prospectus included a table showing a 180-day inventory policy for the primary supplier’s materials and a signed memorandum of understanding with a second-tier supplier for emergency supply. The lesson is clear: disclosure must move beyond stating the percentage to demonstrating operational resilience.

Main Board Rule 11.07 and the “Full, True and Accurate” Standard

Main Board Rule 11.07 requires that a listing document “contain such particulars and information as will enable a reasonable person to form a valid and comprehensive judgment of the issuer and its shares.” The SFC’s “Code of Conduct for Persons Licensed by or Registered with the Securities and Futures Commission” (Chapter 17, paragraph 17.6) further obligates sponsors to ensure that all material risks, including supply chain dependencies, are “adequately and prominently disclosed.” This means a bare statement like “We rely on Supplier X for 40% of our raw materials” is insufficient. The disclosure must include the term of the supply agreement, the notice period for termination, the pricing mechanism (fixed, floating, or formula-based), and any exclusivity clauses. The sponsor’s due diligence must verify these contractual terms against supplier interviews and site visits, with the work program documented in the sponsor’s internal file.

Structuring the Disclosure: From Risk Factor to Business Section

The most common mistake is to confine supplier concentration to a single “Risk Factors” paragraph. HKEX reviewers expect the dependency to be woven into the “Business” section, where the issuer explains why the concentration exists and how it is managed. The risk factor then serves as a cross-reference, not the primary exposition.

The “Business” Section: Framing Dependency as Strategic Specialization

The “Business” section should open the supplier discussion with a positive framing. For instance, a contract electronics manufacturer dependent on a single chip supplier for a specialized component should state: “The Company has entered into a strategic partnership with Supplier A, a global leader in [specific technology], to secure priority access to [component] for a term of five years ending December 2028.” This immediately shifts the narrative from vulnerability to strategic advantage. The section should then detail the supplier’s market position, the length of the relationship, and the historical performance. Data points to include: the number of years of continuous supply (e.g., “12 consecutive years”), the volume of units supplied annually, and the supplier’s own financial health (e.g., “Supplier A reported HKD 45 billion in revenue for FY2023, with an EBITDA margin of 28%”). This demonstrates that the dependency is on a financially sound counterparty.

The “Risk Factors” Section: Quantifying the Impact of a Disruption

The risk factor should quantify the financial impact of a worst-case scenario. Instead of “If our supplier fails to deliver, our business will be harmed,” a compliant disclosure would state: “A six-month disruption in supply from Supplier A would result in an estimated HKD 120 million reduction in revenue for the Company’s fiscal year ending December 2025, representing approximately 15% of the Company’s total projected revenue for that period. This estimate is based on the Company’s current inventory levels of 90 days of finished goods and a 60-day lead time for alternative sourcing from Supplier B, which currently supplies 8% of the Company’s volume.” This level of specificity satisfies the “informed assessment” requirement under Main Board Rule 11.06 because it gives the investor a concrete financial metric to evaluate. The sponsor’s financial due diligence must have stress-tested this scenario, and the working capital forecast in the prospectus should reflect the cash flow implications.

Mitigation Strategies That Pass HKEX Scrutiny

The Exchange does not expect zero dependency; it expects demonstrable management. The most effective prospectuses present a three-pronged mitigation strategy: contractual protections, operational buffers, and financial hedges.

Contractual Protections: The “Take-or-Pay” and “Right of First Refusal” Clauses

A “take-or-pay” clause, common in long-term supply agreements for commodities and specialized components, obligates the buyer to pay for a minimum quantity regardless of actual offtake, while guaranteeing the supplier’s capacity. In a prospectus, the issuer should disclose the minimum purchase obligation (e.g., “HKD 50 million per annum”) and the supplier’s corresponding obligation to reserve capacity (e.g., “80% of Supplier A’s production line for the Company’s specifications”). The “right of first refusal” clause, where the supplier must offer the issuer any excess capacity before selling to third parties, is another strong mitigant. The prospectus should state the clause’s existence, its trigger conditions, and the notice period (e.g., “30 days’ written notice”). The HKEX will ask the sponsor to confirm that these clauses are legally enforceable in the applicable jurisdiction—typically Hong Kong law or the law of the supplier’s domicile, with a clear arbitration clause.

Operational Buffers: Inventory, Dual Sourcing, and In-House Capability

Inventory levels are a critical quantitative mitigant. The prospectus should disclose the average inventory days for the concentrated supplier’s materials, compared to the industry average. For example, a pharmaceutical company dependent on a single active pharmaceutical ingredient (API) supplier might disclose: “The Company maintains an average of 120 days of API inventory, compared to the industry standard of 60 days, to mitigate supply disruptions.” Dual sourcing, even at a small percentage, is a powerful signal. If the issuer has qualified a second supplier for 10-15% of volume, this should be prominently disclosed. The prospectus should state the qualification process (e.g., “Supplier B was qualified in Q3 2023 after a 12-month validation process and has supplied 8% of the Company’s API requirements in FY2024”). In-house capability, even if not fully operational, is also valued. A disclosure that “The Company has completed a pilot production run of the critical component in its own R&D facility, achieving 95% of the primary supplier’s quality specifications,” demonstrates a fallback option.

Financial Hedges: Fixed-Price Contracts and Currency Swaps

For companies with significant raw material exposure, financial hedges are a relevant mitigant. The prospectus should disclose the percentage of procurement covered by fixed-price contracts (e.g., “75% of the Company’s nickel purchases for FY2025 are hedged under fixed-price agreements at an average price of USD 18,500 per tonne”). For cross-border procurement, currency hedging is equally important. The disclosure should state the notional amount of the hedge (e.g., “The Company has entered into USD/HKD swap contracts covering 60% of its USD-denominated payables for the next 12 months, with a strike price range of 7.78 to 7.82”). The sponsor must verify these hedges exist by obtaining the counterparty confirmations and the company’s treasury policy, and the auditor should provide comfort on the accounting treatment under HKFRS 9.

The Sponsor’s Role in Building the Narrative

The sponsor is not a passive reviewer. Under the SFC’s “Code of Conduct” (paragraph 17.6), the sponsor must “take reasonable steps to ensure that any statement or information in the listing document is accurate and complete in all material respects.” For supplier concentration, this means the sponsor’s due diligence team must conduct supplier site visits, interview the supplier’s senior management, and verify the supplier’s own financial statements. The sponsor’s findings are then incorporated into the prospectus as a “Sponsor’s Statement” or a “Due Diligence Summary,” which the Exchange reviews.

The “Sponsor’s Comfort Letter” and Supplier Financial Health

A key deliverable is the sponsor’s comfort letter on the supplier’s financial health. The sponsor should obtain the supplier’s audited financial statements for the most recent three fiscal years. If the supplier is a private company in a jurisdiction like the PRC or BVI, the sponsor may need to rely on management accounts or a limited review by a PRC auditor. The prospectus should disclose the basis of this comfort. For example: “The Sponsor has reviewed Supplier A’s audited financial statements for the years ended 31 December 2022, 2023, and 2024, which were prepared under PRC GAAP. Supplier A’s net profit margin was 12%, 14%, and 13% respectively, and its current ratio was 1.8x, 1.9x, and 1.7x. Based on this review, the Sponsor considers Supplier A to be financially stable.” This level of detail removes the “unknown” that usually causes the Exchange to ask for more information.

The “Alternative Supplier” Verification Process

If the issuer claims to have an alternative supplier, the sponsor must verify that claim. This involves obtaining a letter of intent or a signed supply agreement from the alternative supplier, confirming the pricing, volume, and delivery terms. The sponsor should also verify the alternative supplier’s production capacity and quality certifications. The prospectus should state: “The Sponsor has received a non-binding letter of intent from Supplier C, dated 15 March 2025, indicating its willingness to supply up to 30% of the Company’s requirements for [component] at a price within 5% of the current contract price with Supplier A. Supplier C holds ISO 9001:2015 certification and has an annual production capacity of 10,000 tonnes, which exceeds the Company’s current annual requirement of 6,000 tonnes.” This transforms a qualitative claim into a verifiable data point.

Actionable Takeaways for the Drafting Table

1. Disclose the percentage of procurement from the top supplier(s) for the most recent three fiscal years, and if any single supplier exceeds 30%, prepare a dedicated “Business” section narrative that explains the strategic rationale and contractual term.
2. Quantify the financial impact of a six-month supply disruption in the “Risk Factors” section, using the issuer’s own financial projections and inventory data, and have the sponsor stress-test this scenario in the working capital forecast.
3. Include a table in the prospectus comparing the issuer’s inventory days for the critical material against the industry average, and disclose any dual-sourcing arrangements with a qualified second supplier, even if the volume is as low as 10%.
4. For any supplier concentration exceeding 50%, obtain a sponsor’s comfort letter on the supplier’s financial health, including audited financials or management accounts, and disclose the key financial ratios in the prospectus.
5. Ensure the sponsor’s due diligence file contains a signed letter of intent or supply agreement from any claimed alternative supplier, with verified production capacity and quality certifications, to satisfy the SFC’s “reasonable steps” requirement under the Code of Conduct.